Ming Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ming Yang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Mei He
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
4 shared publications- Xiaopeng Ai
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; Department of Pharmacy, North Sichuan Medical College, Nanchong 637000, China
4 shared publications Yue Zhou
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
4 shared publicationsFeng Li
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
3 shared publicationsJing Wang
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; Department of Pharmacy, North Sichuan Medical College, Nanchong 637000, China
3 shared publicationsRui Li
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
3 shared publications
Latest Publications
- 15 July 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt A) , 120290
Siwei Jianghuang Decoction mitigates diabetic nephropathy by suppressing oxidative stress, inflammation and apoptosis via the inhibition of the NOX-4/NF-κB/MCP-1 pathway
- 15 July 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt A) , 120290
Siwei Jianghuang Decoction mitigates diabetic nephropathy by suppressing oxidative stress, inflammation and apoptosis via the inhibition of the NOX-4/NF-κB/MCP-1 pathway
- 23 November 2024
- Published by Springer Nature in Current Microbiology
- Vol. 82 (1) , 1-9
H-NS-Mediated Regulation of Swimming Motility and Polar Flagellar Gene Expression in Vibrio parahaemolyticus
Vibrio parahaemolyticus is equipped with two distinct flagellar systems: a polar flagellum and numerous lateral flagella. The polar flagellum plays a role in propelling swimming in liquids, while the lateral flagella serve to enhance swarming on surfaces or in viscous environments. H-NS is a histone-like nucleoid structuring protein that plays a regulatory role in both the swimming and swarming motility of V. parahaemolyticus. However, the detailed mechanisms have not been fully understood. In this study, we have demonstrated that the deletion of hns hindered the growth rate of V. parahaemolyticus during the logarithmic growth phase and significantly decreased the swimming motility. H-NS directly activated the transcription of flgMN, flgAMN, flgBCDEFGHIJ, and flgKL-flaC located within the polar flagellar gene clusters. The expression of H-NS in Escherichia coli led to a marked elevation in the expression levels of flgM, flgA, flgB, and flgK, suggesting the positive effect of H-NS on the expression of polar flagellar genes in E. coli. This work demonstrates that the positive regulation of H-NS on the swimming motility in V. parahaemolyticus may be achieved through its regulation of polar flagellar gene expression and bacterial growth.
- 23 November 2024
- Published by Springer Nature in Current Microbiology
- Vol. 82 (1) , 1-9
H-NS-Mediated Regulation of Swimming Motility and Polar Flagellar Gene Expression in Vibrio parahaemolyticus
Vibrio parahaemolyticus is equipped with two distinct flagellar systems: a polar flagellum and numerous lateral flagella. The polar flagellum plays a role in propelling swimming in liquids, while the lateral flagella serve to enhance swarming on surfaces or in viscous environments. H-NS is a histone-like nucleoid structuring protein that plays a regulatory role in both the swimming and swarming motility of V. parahaemolyticus. However, the detailed mechanisms have not been fully understood. In this study, we have demonstrated that the deletion of hns hindered the growth rate of V. parahaemolyticus during the logarithmic growth phase and significantly decreased the swimming motility. H-NS directly activated the transcription of flgMN, flgAMN, flgBCDEFGHIJ, and flgKL-flaC located within the polar flagellar gene clusters. The expression of H-NS in Escherichia coli led to a marked elevation in the expression levels of flgM, flgA, flgB, and flgK, suggesting the positive effect of H-NS on the expression of polar flagellar genes in E. coli. This work demonstrates that the positive regulation of H-NS on the swimming motility in V. parahaemolyticus may be achieved through its regulation of polar flagellar gene expression and bacterial growth.
- 15 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 3) , 113570
Gut microbiota contributes to the intestinal and extraintestinal immune homeostasis by balancing Th17/Treg cells
- 15 November 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 3) , 113570
Gut microbiota contributes to the intestinal and extraintestinal immune homeostasis by balancing Th17/Treg cells
- 6 July 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 275 (Pt 2) , 133686
Preparation techniques, structural features, and bioactivities of Eucommia ulmoides polysaccharides: A review
- 6 July 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 275 (Pt 2) , 133686
Preparation techniques, structural features, and bioactivities of Eucommia ulmoides polysaccharides: A review
- Top Cited Papers
- 6 April 2024
- Published by Elsevier in Life Sciences
- Vol. 345, 122612
Gut microbiota as a key regulator of intestinal mucosal immunity
- 6 April 2024
- Published by Elsevier in Life Sciences
- Vol. 345, 122612
Top Cited PapersGut microbiota as a key regulator of intestinal mucosal immunity
- 1 January 2024
- Published by Shanghai Institute of Organic Chemistry in Acta Chimica Sinica
- Vol. 82 (7) , 772-781
Metal Ion-gemcitabine Monophosphate Nanoparticles for Effective Treatment of Pancreatic Cancer
- 1 January 2024
- Published by Shanghai Institute of Organic Chemistry in Acta Chimica Sinica
- Vol. 82 (7) , 772-781
Metal Ion-gemcitabine Monophosphate Nanoparticles for Effective Treatment of Pancreatic Cancer
- 7 May 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (8) , 1227-1238
Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid
Purpose To investigate the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid (MPA). Methods PubMed, Web of Science, Embase, Cochrane Library, Wanfang Data, and the China Academic Journal Network Publishing Database were systematically searched for studies investigating the associations of IMPDH1, IMPDH2, and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking MPA. Associations were evaluated by pooled odds ratios (ORs) and effect sizes (ESs) with 95% confidence intervals (CIs). Results Twelve studies were included in the analysis, including a total of 2342 kidney transplant recipients. The results showed that compared with the TC + CC variant genotypes, the TT genotype of IMPDH2 3757 T > C was significantly associated with a higher risk of rejection (ES = 1.60, 95% CI = 1.07–2.40, P = 0.021), while there was no significant association of the IMPDH2 3757 T > C polymorphism with acute rejection within 1 year in kidney transplant recipients (OR = 1.49, 95% CI = 0.79–2.80, P = 0.217; ES = 1.44, 95% CI = 0.88–2.36, P = 0.142). The GG genotypes of IMPDH1 125G > A and IMPDH1 106G > A were significantly associated with a higher risk of rejection (ES = 1.91, 95% CI = 1.11–3.28, P = 0.019) and acute rejection within 1 year (ES = 2.12, 95% CI = 1.45–3.10, P < 0.001) than the variant genotypes GA + AA. The TT genotype of UGT1A9 275 T > A showed a decreased risk of rejection compared with the variant genotypes TA + AA (ES = 0.44, 95% CI = 0.23–0.84, P = 0.013). Conclusions IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA.
- 7 May 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (8) , 1227-1238
Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid
Purpose To investigate the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid (MPA). Methods PubMed, Web of Science, Embase, Cochrane Library, Wanfang Data, and the China Academic Journal Network Publishing Database were systematically searched for studies investigating the associations of IMPDH1, IMPDH2, and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking MPA. Associations were evaluated by pooled odds ratios (ORs) and effect sizes (ESs) with 95% confidence intervals (CIs). Results Twelve studies were included in the analysis, including a total of 2342 kidney transplant recipients. The results showed that compared with the TC + CC variant genotypes, the TT genotype of IMPDH2 3757 T > C was significantly associated with a higher risk of rejection (ES = 1.60, 95% CI = 1.07–2.40, P = 0.021), while there was no significant association of the IMPDH2 3757 T > C polymorphism with acute rejection within 1 year in kidney transplant recipients (OR = 1.49, 95% CI = 0.79–2.80, P = 0.217; ES = 1.44, 95% CI = 0.88–2.36, P = 0.142). The GG genotypes of IMPDH1 125G > A and IMPDH1 106G > A were significantly associated with a higher risk of rejection (ES = 1.91, 95% CI = 1.11–3.28, P = 0.019) and acute rejection within 1 year (ES = 2.12, 95% CI = 1.45–3.10, P < 0.001) than the variant genotypes GA + AA. The TT genotype of UGT1A9 275 T > A showed a decreased risk of rejection compared with the variant genotypes TA + AA (ES = 0.44, 95% CI = 0.23–0.84, P = 0.013). Conclusions IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA.
- Open Access
- 15 December 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e933688-1-e933688-9
Risk Factors for Cryptococcal Meningitis Recurrence in Human Immunodeficiency Virus (HIV)-Infected Patients in a Large Chinese Acquired Immune Deficiency Syndrome (AIDS) Treatment Center
Background: Cryptococcal meningitis (CM) is one of the most common opportunistic neuroinfections in patients with HIV. Most studies have focused on non-HIV CM and there are only a few studies on HIV CM in China. The purpose of the present study was to evaluate the characteristics and risk factors for CM recurrence in patients infected with HIV in the Chongqing Public Health Treatment Center in China. Material/Methods: From January 2014 to December 2017, all patients with CM aged 18 years or older were enrolled and a case control study was performed to determine the risk factors associated with recurrence of CM. Antimicrobial susceptibility was determined with a fungal drug sensitivity kit and the sequence types (STs) were analyzed with multilocus sequence typing. Results: The incidence of CM in the 5185 HIV-infected patients was 3.5% (179). Follow-up data were available for 82 of the patients for whom complete medical records were available and they were included in the present study. There were 7 STs among 82 Cryptococcus neoformans isolates; ST5 and ST31 were the most prevalent genotypes. Testing showed that C. neoformans had high sensitivity to 5 antifungal drugs and no differences in resistance were observed, even when different STs were tested. Risk factors for recurrence were analyzed in 69 patients, excluding those who died. The results of multivariate analysis showed that only hospital stay was associated with recurrence of CM. Conclusions: Our results indicated that combining education about medication with clinical treatment could help prevent recurrence of CM.
- 15 December 2021
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e933688-1-e933688-9
Open AccessRisk Factors for Cryptococcal Meningitis Recurrence in Human Immunodeficiency Virus (HIV)-Infected Patients in a Large Chinese Acquired Immune Deficiency Syndrome (AIDS) Treatment Center
Background: Cryptococcal meningitis (CM) is one of the most common opportunistic neuroinfections in patients with HIV. Most studies have focused on non-HIV CM and there are only a few studies on HIV CM in China. The purpose of the present study was to evaluate the characteristics and risk factors for CM recurrence in patients infected with HIV in the Chongqing Public Health Treatment Center in China. Material/Methods: From January 2014 to December 2017, all patients with CM aged 18 years or older were enrolled and a case control study was performed to determine the risk factors associated with recurrence of CM. Antimicrobial susceptibility was determined with a fungal drug sensitivity kit and the sequence types (STs) were analyzed with multilocus sequence typing. Results: The incidence of CM in the 5185 HIV-infected patients was 3.5% (179). Follow-up data were available for 82 of the patients for whom complete medical records were available and they were included in the present study. There were 7 STs among 82 Cryptococcus neoformans isolates; ST5 and ST31 were the most prevalent genotypes. Testing showed that C. neoformans had high sensitivity to 5 antifungal drugs and no differences in resistance were observed, even when different STs were tested. Risk factors for recurrence were analyzed in 69 patients, excluding those who died. The results of multivariate analysis showed that only hospital stay was associated with recurrence of CM. Conclusions: Our results indicated that combining education about medication with clinical treatment could help prevent recurrence of CM.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non‐Small‐Cell Lung Cancer: A Meta‐Analysis of Randomized Controlled Trials
Objective. Bevacizumab was currently available for nonsquamous non‐small‐cell lung cancer (NSqNSCLC) patients and has been studied in several randomized controlled trials (RCTs) for treatment of these patients. This meta‐analysis summarizes the most up‐to‐date evidences regarding the effects and adverse reactions of bevacizumab in the treatment of NSqNSCLC patients. Methods. The authors searched for RCTs from electronic database including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Experimental arm was defined as the bevacizumab‐containing group and the control arm as the bevacizumab‐free group. Data of objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and adverse reactions were synthetically extracted. A protocol for this meta‐analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero). Results. Ten RCTs that involved a total of 3134 patients were included. The experimental group was associated with significant superior ORR (RR 1.63, 95% CI 1.24 to 2.14, P < 0.001), OS (HR 0.90, 95% CI 0.82 to 0.99, P < 0.001), and prolonged PFS (HR 0.68, 95% CI 0.62 to 0.74, P < 0.001) compared to the control. No significant difference was observed regarding DCR (RR 1.13, 95% CI 0.99 to 1.30, P = 0.08). The experimental group showed higher rate of hypertension (RR 6.91, 95% CI 4.62 to 10.35, P < 0.00001) and hemorrhagic events (RR 3.07, 95% CI 1.78 to 5.30, P < 0.0001) than the control group. The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02) than the control group. No significant difference was observed regarding treatment‐related adverse event grade 3‐5 (TRAE3‐5) (RR 1.23, 95% CI 0.99 to 1.53, P = 0.06), thrombocytopenia (RR 1.11, 95% CI 0.92 to 1.33, P = 0.29), and neutropenia (RR 1.11, 95% CI 0.88 to 1.40, P = 0.36). Conclusion. This meta‐analysis showed that bevacizumab could increase ORR, OS, and prolonged PFS for treatment of NSqNSCLC patients. However, no significant improvement in DCR was observed and bevacizumab could increase the rate of hypertension and hemorrhagic events. Bevacizumab was an acceptable option for NSqNSCLC patients. This trial is registered with PROSPERO registration number: CRD42021226790.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessThe Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non‐Small‐Cell Lung Cancer: A Meta‐Analysis of Randomized Controlled Trials
Objective. Bevacizumab was currently available for nonsquamous non‐small‐cell lung cancer (NSqNSCLC) patients and has been studied in several randomized controlled trials (RCTs) for treatment of these patients. This meta‐analysis summarizes the most up‐to‐date evidences regarding the effects and adverse reactions of bevacizumab in the treatment of NSqNSCLC patients. Methods. The authors searched for RCTs from electronic database including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Experimental arm was defined as the bevacizumab‐containing group and the control arm as the bevacizumab‐free group. Data of objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and adverse reactions were synthetically extracted. A protocol for this meta‐analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero). Results. Ten RCTs that involved a total of 3134 patients were included. The experimental group was associated with significant superior ORR (RR 1.63, 95% CI 1.24 to 2.14, P < 0.001), OS (HR 0.90, 95% CI 0.82 to 0.99, P < 0.001), and prolonged PFS (HR 0.68, 95% CI 0.62 to 0.74, P < 0.001) compared to the control. No significant difference was observed regarding DCR (RR 1.13, 95% CI 0.99 to 1.30, P = 0.08). The experimental group showed higher rate of hypertension (RR 6.91, 95% CI 4.62 to 10.35, P < 0.00001) and hemorrhagic events (RR 3.07, 95% CI 1.78 to 5.30, P < 0.0001) than the control group. The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02) than the control group. No significant difference was observed regarding treatment‐related adverse event grade 3‐5 (TRAE3‐5) (RR 1.23, 95% CI 0.99 to 1.53, P = 0.06), thrombocytopenia (RR 1.11, 95% CI 0.92 to 1.33, P = 0.29), and neutropenia (RR 1.11, 95% CI 0.88 to 1.40, P = 0.36). Conclusion. This meta‐analysis showed that bevacizumab could increase ORR, OS, and prolonged PFS for treatment of NSqNSCLC patients. However, no significant improvement in DCR was observed and bevacizumab could increase the rate of hypertension and hemorrhagic events. Bevacizumab was an acceptable option for NSqNSCLC patients. This trial is registered with PROSPERO registration number: CRD42021226790.
- 20 April 2010
- Published by China Science Publishing & Media Ltd. in JOURNAL OF HUNAN AGRICULTURAL UNIVERSITY
- Vol. 36 (2) , 123-127
Screening of the AFLP markers linked to the sex locus of Cannabis sativa
- 20 April 2010
- Published by China Science Publishing & Media Ltd. in JOURNAL OF HUNAN AGRICULTURAL UNIVERSITY
- Vol. 36 (2) , 123-127
Screening of the AFLP markers linked to the sex locus of Cannabis sativa